Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Protective effect of vaccination against mumps complications, Czech Republic, 2007-2012

H. Orlíková, M. Malý, P. Lexová, H. Šebestová, R. Limberková, L. Jurzykowská, J. Kynčl,

. 2016 ; 16 (-) : 293. [pub] 20160401

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
NT14059 MZ0 CEP Register

BACKGROUND: In the Czech Republic, two-dose immunization against mumps achieves 98% coverage. The routine reporting detects mumps cases, clinical complications, and hospital admissions in unvaccinated but also in vaccinated individuals. Using surveillance data of patients with mumps we assessed the effectiveness of mumps vaccination on mumps clinical complications and hospitalization need. We also investigated the effect of the time since immunization. METHODS: We analysed data on incident mumps cases reported to the Czech national surveillance system in 2007-2012. Using a logistic regression model with adjustment for age, sex, year of onset, and the administrative region, the association between vaccination and the most frequent mumps complications and hospitalization was evaluated. The adjusted odds ratios (ORa) for mumps complications were compared between the vaccinated and non-vaccinated groups, reflecting the vaccine effectiveness (VEa) computed as VEa = (1-ORa) × 100. We estimated the risk of mumps complications by the time from vaccination. RESULTS: From total of 9663 mumps analysed cases 5600 (58%) occurred in males. The mean age at the disease onset was 17.3, median 16 years. Ninety percent of the study patients had no complications, while 1.6% developed meningitis, 0.2% encephalitis, and 0.6% pancreatitis. Mumps orchitis occurred in 659 (11.8%) male cases. In total, 1192 (12.3%) patients required hospitalization. Two doses of vaccine received by 81.8% cases significantly reduced the risk of hospitalization: ORa 0.29 (95% CI: 0.24, 0.35). Two doses showed statistically significant VEa 64% (95% CI: 46, 79) for meningitis, 93% (95% CI: 66, 98) for encephalitis in all cases, and 72% (95% CI: 64, 78) for orchitis in males. Vaccine effectiveness for orchitis declined from 81 to 74% and 56% in the most affected age groups 10-14, 15-19, and 20-24 years, respectively. Among 7850 two-dose recipients, the rate of complications rose from below 1 to 16% in categories up to 6 years and 24 and more years after the second dose, respectively. CONCLUSIONS: This study demonstrates a significant preventive effect of two-dose vaccination against mumps complications (orchitis, meningitis, or encephalitis) and hospitalization for mumps. The risk of complications increases with time interval from vaccination. Teenagers and young adults were the most affected age groups.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000305
003      
CZ-PrNML
005      
20181210090753.0
007      
ta
008      
170103s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12889-016-2958-4 $2 doi
024    7_
$a 10.1186/s12889-016-2958-4 $2 doi
035    __
$a (PubMed)27036176
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Orlíková, Hana, $d 1965- $7 xx0218806 $u Department of Infectious Diseases Epidemiology, Centre for Epidemiology and Microbiology, National Institute of Public Health, Šrobárova 48, 10042, Prague, Czech Republic. hana.orlikova@szu.cz.
245    10
$a Protective effect of vaccination against mumps complications, Czech Republic, 2007-2012 / $c H. Orlíková, M. Malý, P. Lexová, H. Šebestová, R. Limberková, L. Jurzykowská, J. Kynčl,
520    9_
$a BACKGROUND: In the Czech Republic, two-dose immunization against mumps achieves 98% coverage. The routine reporting detects mumps cases, clinical complications, and hospital admissions in unvaccinated but also in vaccinated individuals. Using surveillance data of patients with mumps we assessed the effectiveness of mumps vaccination on mumps clinical complications and hospitalization need. We also investigated the effect of the time since immunization. METHODS: We analysed data on incident mumps cases reported to the Czech national surveillance system in 2007-2012. Using a logistic regression model with adjustment for age, sex, year of onset, and the administrative region, the association between vaccination and the most frequent mumps complications and hospitalization was evaluated. The adjusted odds ratios (ORa) for mumps complications were compared between the vaccinated and non-vaccinated groups, reflecting the vaccine effectiveness (VEa) computed as VEa = (1-ORa) × 100. We estimated the risk of mumps complications by the time from vaccination. RESULTS: From total of 9663 mumps analysed cases 5600 (58%) occurred in males. The mean age at the disease onset was 17.3, median 16 years. Ninety percent of the study patients had no complications, while 1.6% developed meningitis, 0.2% encephalitis, and 0.6% pancreatitis. Mumps orchitis occurred in 659 (11.8%) male cases. In total, 1192 (12.3%) patients required hospitalization. Two doses of vaccine received by 81.8% cases significantly reduced the risk of hospitalization: ORa 0.29 (95% CI: 0.24, 0.35). Two doses showed statistically significant VEa 64% (95% CI: 46, 79) for meningitis, 93% (95% CI: 66, 98) for encephalitis in all cases, and 72% (95% CI: 64, 78) for orchitis in males. Vaccine effectiveness for orchitis declined from 81 to 74% and 56% in the most affected age groups 10-14, 15-19, and 20-24 years, respectively. Among 7850 two-dose recipients, the rate of complications rose from below 1 to 16% in categories up to 6 years and 24 and more years after the second dose, respectively. CONCLUSIONS: This study demonstrates a significant preventive effect of two-dose vaccination against mumps complications (orchitis, meningitis, or encephalitis) and hospitalization for mumps. The risk of complications increases with time interval from vaccination. Teenagers and young adults were the most affected age groups.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a Česká republika $x epidemiologie $7 D018153
650    _2
$a encefalitida $x epidemiologie $x prevence a kontrola $7 D004660
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hospitalizace $x statistika a číselné údaje $7 D006760
650    _2
$a lidé $7 D006801
650    _2
$a očkovací schéma $7 D007115
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a meningitida $x epidemiologie $x prevence a kontrola $7 D008581
650    _2
$a lidé středního věku $7 D008875
650    _2
$a příušnice $x komplikace $x epidemiologie $x prevence a kontrola $7 D009107
650    _2
$a vakcína proti příušnicím $x aplikace a dávkování $7 D009108
650    _2
$a orchitida $x epidemiologie $x prevence a kontrola $7 D009920
650    12
$a surveillance populace $7 D011159
650    _2
$a riziko $7 D012306
650    _2
$a časové faktory $7 D013997
650    _2
$a vakcinace $x statistika a číselné údaje $7 D014611
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Malý, Marek $u Department of Biostatistics, National Institute of Public Health, Šrobárova 48, 10042, Prague, Czech Republic.
700    1_
$a Lexová, Pavla $u Department of Infectious Diseases Epidemiology, Centre for Epidemiology and Microbiology, National Institute of Public Health, Šrobárova 48, 10042, Prague, Czech Republic.
700    1_
$a Šebestová, Helena $u Department of Biostatistics, National Institute of Public Health, Šrobárova 48, 10042, Prague, Czech Republic.
700    1_
$a Limberková, Radomíra $u National Reference Laboratory for Measles, Mumps, Rubella and Parvovirus B19, Centre for Epidemiology and Microbiology, National Institute of Public Health, Šrobárova 48, 10042, Prague, Czech Republic.
700    1_
$a Jurzykowská, Lucie $u Department of Infectious Diseases Epidemiology, Centre for Epidemiology and Microbiology, National Institute of Public Health, Šrobárova 48, 10042, Prague, Czech Republic.
700    1_
$a Kynčl, Jan $u Department of Infectious Diseases Epidemiology, Centre for Epidemiology and Microbiology, National Institute of Public Health, Šrobárova 48, 10042, Prague, Czech Republic. Department of Epidemiology, 3rd Faculty of Medicine, Charles University in Prague, Ruská 87, 10000, Prague, Czech Republic.
773    0_
$w MED00008205 $t BMC public health $x 1471-2458 $g Roč. 16, č. - (2016), s. 293
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27036176 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20181210090914 $b ABA008
999    __
$a ok $b bmc $g 1179445 $s 960872
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 16 $c - $d 293 $e 20160401 $i 1471-2458 $m BMC public health $n BMC Public Health $x MED00008205
GRA    __
$a NT14059 $p MZ0
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...